
Mirabegron (25mg) + Solifenacin (5mg)
Active composition
+1 more active ingredient
Solifenacin antagonizes muscarinic receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Medical applications
Mirakem S 25mg/5mg Tablet is a fixed-dose combination product containing mirabegron, a beta-3 adrenergic receptor agonist, and solifenacin, a selective muscarinic receptor antagonist. This oral therapy is indicated for the treatment of overactive bladder (OAB) with symptoms of urgency, frequency, and nocturia. Mirabegron's beta-3 receptor activation stimulates detrusor muscle relaxation, reducing bladder contractions and increasing functional bladder capacity. Simultaneously, solifenacin's selective muscarinic receptor antagonism blocks the effects of acetylcholine on the bladder and urethra, thereby reducing detrusor muscle contractions and urinary frequency. The combination of mirabegron and solifenacin in Mirakem S 25mg/5mg Tablet provides a synergistic therapeutic effect, addressing the complex pathophysiology of OAB. The recommended dosage is one tablet once daily, with or without food. As with any medication, patients should be counseled on the potential risks and benefits, including the possibility of anticholinergic adverse effects, such as dry mouth, constipation, and blurred vision.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Mirakem S 25mg/5mg Tablet during pregnancy is not available. Please consult your doctor.
High Risk
Information regarding the use of Mirakem S 25mg/5mg Tablet during breastfeeding is not available. Please consult your doctor.
Medical Advice
There is limited information available on the use of Mirakem S 25mg/5mg Tablet in patients with kidney disease. Please consult your doctor.
Exercise Caution
It is not known whether Mirakem S 25mg/5mg Tablet alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
There is limited information available on the use of Mirakem S 25mg/5mg Tablet in patients with liver disease. Please consult your doctor.
Regular Checkup
0 reviews for Mirakem S 25mg/5mg Tablet

Mirabegron (25mg) + Solifenacin (5mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Solifenacin antagonizes muscarinic receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Medical applications
Mirakem S 25mg/5mg Tablet is a fixed-dose combination product containing mirabegron, a beta-3 adrenergic receptor agonist, and solifenacin, a selective muscarinic receptor antagonist. This oral therapy is indicated for the treatment of overactive bladder (OAB) with symptoms of urgency, frequency, and nocturia. Mirabegron's beta-3 receptor activation stimulates detrusor muscle relaxation, reducing bladder contractions and increasing functional bladder capacity. Simultaneously, solifenacin's selective muscarinic receptor antagonism blocks the effects of acetylcholine on the bladder and urethra, thereby reducing detrusor muscle contractions and urinary frequency. The combination of mirabegron and solifenacin in Mirakem S 25mg/5mg Tablet provides a synergistic therapeutic effect, addressing the complex pathophysiology of OAB. The recommended dosage is one tablet once daily, with or without food. As with any medication, patients should be counseled on the potential risks and benefits, including the possibility of anticholinergic adverse effects, such as dry mouth, constipation, and blurred vision.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Mirakem S 25mg/5mg Tablet during pregnancy is not available. Please consult your doctor.
High Risk
Information regarding the use of Mirakem S 25mg/5mg Tablet during breastfeeding is not available. Please consult your doctor.
Medical Advice
There is limited information available on the use of Mirakem S 25mg/5mg Tablet in patients with kidney disease. Please consult your doctor.
Exercise Caution
It is not known whether Mirakem S 25mg/5mg Tablet alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
There is limited information available on the use of Mirakem S 25mg/5mg Tablet in patients with liver disease. Please consult your doctor.
Regular Checkup
0 reviews for Mirakem S 25mg/5mg Tablet















